anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to liquid medicinal form of naltrexone designated for internal using. Liquid medicinal form of naltrexone comprises the following composition: naltrexone hydrochloride (as measured for 100% substance), sorbit 70%, taste regulating agent, sweetening agent, antibacterial preserving agent, ethyl alcohol, purified water taken in the definite ratio of components. Invention provides accelerating effect of proposed preparation. EFFECT: valuable medicinal and pharmaceutical properties of preparation. 2 ex
The invention relates to a preparation method of total glucosides from Paeonia lactiflora Pall., and a Paeonia lactiflora Pall. total glucoside preparation and use thereof. The method comprises: grinding, extracting, concentrating under reduced pressure, extracting, decolorizing, filtering, re-concentrating and drying. Column chromatography also can be used. The preparation method provided by the invention greatly improves the content of total glucosides from Paeonia lactiflora Pall. to over 80 percent. The total glucosides from Paeonia lactiflora Pall., which is provided by the invention, can be used in the preparation of medicines for treating gynecological diseases, in particular the use in the preparation of medicines for treating dysmenorrheal, abnormal menstruation or endometriosis. The preparation method simplifies operation, adopts extraction solvent with low toxicity, allows for easy solvent recovery, is friendly to human beings and the environment and in accordance with environment protection requirements.
2114942 9303050 PCTABS00019 The cloning and characterization of a new binding protein class, cyclophilin C (cyp C) and homologous proteins, is provided which is capable of binding to, e.g., the immunosuppressive drug cyclosporin A (CsA). The pattern of cyp C mRNA expression differs from that of cyp A mRNA expression, with cyp C being expressed in a more restricted subset of tissues, including those tissues reported to be most affected by CsA therapy. A fusion protein containing, e.g., amino acids 16-212 of cyp C has peptidyl-prolyl-isomerase activity (PPIase), and CsA inhibits this activity. Most significantly, these cyp C fusion proteins can be used as ligands for the identification of intracellular proteins which together form high affinity associations. For example, the cyp C fusion protein binds specifically to a protein of 77 Kd in the absence of CsA, while in the presence of CsA it no longer binds to this p77, but instead binds specifically to a protein 55 Kd, identified as calcineurin (see U.S.S.N. 07/740,175, incorporated herein by reference).
The invention relates to a preparation method and application of a hyaluronic acid modified metal organic framework nano preparation loaded with glucose oxidase, and belongs to the technical field of nano medicines. Is prepared from copper nitrate trihydrate, 2,3,6,7,10, 11-hexahydroxytriphenyl, tris (hydroxymethyl) aminomethane, sodium hyaluronate and glucose oxidase. Under the irradiation of near infrared laser, the hyaluronic acid modified metal organic framework nano preparation can generate good photo-thermal performance, and can kill tumor cells by utilizing high temperature; meanwhile, the nano preparation can consume glutathione and destroy the oxidation-reduction balance in tumor cells. Modification of hyaluronic acid may enhance enrichment of the nanoformulation at the tumor site. In addition, the loaded glucose oxidase can consume glucose, so as to realize starvation therapy of tumors and enhance chemical kinetics effects, thereby realizing good anti-tumor effects. The preparation method is simple and can realize large-scale production.
This will involve sustained periods of 90-seconds of hyperventilation at two levels (-5mmHg and -10mmHg below baseline EtCO2) to a maximum lower level threshold of EtCO2 24mmHg/CBFV 33cm/s regulated using a metronome. Two-minute washout periods of normal respiration will be allowed between successive measurements. Each incremental reduction in pCO2 will be repeated on two occasions during the same session. Further assessments will be conducted 10-14 days following baseline assessments.
Chronic pain conditions are among the most common reasons adults seek medical care. Given the abuse potential for opioid analgesics, a substantial number of individuals with chronic pain have turned to alternatives such as medical marijuana. There is increasing evidence that medical marijuana has potential benefits for pain related conditions, but it also carries unwanted side effects such as impaired cognition and motor skills that may linger long after use, social stigma, and a moderate potential for abuse. Much of the marijuana/pain research is predicated on the assumption that its potential analgesic effects are due to its primary psychoactive ingredient - delta-9-tetrahydrocannabinol (THC). However, marijuana also contains dozens of phytochemicals, including cannabinoids and terpenes. Accordingly, there is interest in characterizing potential pain-relieving effects of these non-intoxicating constituents of marijuana. Thus far, it is unclear which components may be most relevant for influencing pain, or the mechanisms by which they exert their effects. Betacaryophyllene (BCP) may be a possible candidate because it is isolatable, has shown evidence as a potential analgesic in preclinical research, is known to be safe for human administration, and there is a strong premise for believing it interacts with the neurobiological systems in the brain that process pain.

This project was conceptualized to advance our mechanistic understanding of the analgesic potential of BCP in humans. The study will be a randomized, placebo-controlled, double-blind study of the pharmacokinetic mechanisms of BCP, including dosing and duration of action, and its potential analgesic effect on thermal pain induction following single-oral dosage. Ten healthy participants will be screened and on each of four subsequent visits will be dosed with either 5 mg, 30 mg, 150 mg of BCP or placebo. Participants' sensitivity to thermal pain induction will be measured before and after administration of the drug using a self survey of pain level. Successful completion of the project may elucidate the potential analgesic effects of ingesting beta-caryophyllene in humans, which can lead to new forms of treatment for pain.
Electrocardiogram of a patient affected by hypertrophic cardiomyopathy showed normal PR and QRS intervals and signs of left ventricular hypertrophy. In leads I,V5 and V6 the initial q waves were absent. A subsequent electrocardiogram revealed the appearance of prominent anterior QRS forces expressed by a change from rS to R pattern in leads V2 and V3 with a tall R wave in V2. PR and QRS intervals and QRS axis remained substantially unchanged. Other electrocardiograms showed day-to-day variations of the anterior displacement of QRS complex. The different degrees of anterior displacement appear to be an expression of an underlying left septal fascicular block, but a diagnosis cannot be made with certainty.
Whole blood can be ABO-type specific (type-specific whole blood (TSWB)) or low-titer O universal donor (low-titer O whole blood (LTOWB)). Having previously used LTOWB, the US Armed Forces Blood Program began using TSWB in 1965 as a method of increasing the donor pool. In contrast to military practice, the Association for the Advancement of Blood and Biotherapies formerly the American association of blood banks (AABB), from its first guidelines in 1958 until 2018, permitted only TSWB. Attempting to reduce time to transfusion, the US military reintroduced LTOWB in the deployed environment in 2015; this practice was endorsed by the AABB in 2018 and is progressively being implemented by military and civilian providers worldwide. Low-titer O whole blood is the only practical solution prehospital. However, there are several reasons to retain the option of TSWB in hospitals with a laboratory. These include (1) as-yet ill-defined risks of immunological complications from ABO-incompatible plasma (even when this has low titers of anti-A and -B), (2) risks of high volumes of LTOWB including published historical advice (based on clinical experience) not to transfuse type-specific blood for 2 to 3 weeks following a substantial LTOWB transfusion, (3) uncertainty as to the optimal definition of "low titer," and (4) expanding the potential donor pool by allowing type-specific transfusion. Several large randomized controlled trials currently underway are comparing LTOWB with component therapy, but none address the question of LTOWB versus TSWB. There are sufficient data to suggest that the additional risks of transfusing LTOWB to non-group O recipients should be avoided by using TSWB as soon as possible. Combined with the advantage of maintaining an adequate supply of blood products in times of high demand, this suggests that retaining TSWB within the civilian and military blood supply system is desirable. TSWB should be preferred when patient blood group is confirmed in facilities with a hematology laboratory, with LTOWB reserved for patients whose blood group is unknown.
Patients undergoing major orthopedic surgery frequently require blood transfusions both during and after the operation. Agents that can increase the rate of red blood cell production would reduce the need for blood transfusions. Epoetin alfa is a genetically engineered form of a natural hormone, erythropoietin, that stimulates red blood cell production. This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study. The study compares the effectiveness of epoetin alfa in reducing the need for blood transfusions in patients who are expected to require at least 2 units of blood following major orthopedic surgery. Eligible patients will be randomly assigned to receive either epoetin alfa (100 or 300 U/kg, depending upon their body weight) or a matching placebo, by injection beneath the skin starting 10 days before scheduled surgery, on the day of surgery (after surgery), and for 4 days after surgery. Additionally, all patients will start taking an oral iron supplement at least 10 days before their scheduled surgery. Effectiveness will be determined by the number of transfusions required following surgery, and on changes in hematocrit (iron-containing pigment in red blood cells), hemoglobin (oxygen-carrying component of red blood cells), and reticulocyte (immature red blood cells) levels from the start of the study to the end of the study. Safety evaluations will include the incidence and severity of adverse events, and changes in clinical laboratory tests, vital signs, and physical examination findings throughout the study. The study hypothesis is that patients treated with epoetin alfa will require fewer blood transfusions after surgery than patients treated with placebo. Epoetin alfa (300 U/kg or 100 U/kg), or matching placebo, by injection beneath the skin beginning 10 days before scheduled surgery and ending 4 days after surgery.
Phase I: An open label study of 3 patients will be done. If no dose limiting toxic (DLT) side effects occur, then an additional 3 patients will be done. If no DLT events occur, the study will proceed to Phase II.
A pre-post pilot study will be conducted. Participants will be referred to the study from 'Maccabi Healthcare Services' by family physicians and geriatric physician of 'Maccabi Healthcare Services Central District'. The majority of TECH protocol training will take place in the participants' home as self-practice. The assessment and weekly group meetings will take place at clinics of Maccabi Healthcare Services in the Central District. A Helsinki approval (#2016009) has already been obtained. Participants will receive information regarding the study and if eligible will sign a consent form, undergo the screening and then the pre-intervention assessments. Then they will receive the TECH protocol, and following the intervention a second assessment will be performed.
The invention relates to cold therapy gel. The cold therapy gel comprises, by mass (in units of 500g) 5g-15g of Carbomer940GE, 25g-35g of ethanol, 5g-15g of peppermint and the balance de-ionized water. Volatile liquid gel is adopted as the cold therapy gel and contains the peppermint, the water and macromolecular substances. The roll-on mode is adopted, and effective components of the finished gel are directly spread on the forehead, the temples, the neck, the armpits, the inner sides of the thighs, soft tissue contusion parts, an arthralgia part and other parts. Cold therapy and physical cooling are performed on a fever patient, an acute sprain patient, a soft tissue contusion patient, a heatstroke patient and other patients by utilizing the principle of the cold therapy. The cold therapy gel prevents heatstroke, refreshes people and has the advantages of being fast in defervescence, safe, reliable, free of side effects, convenient to use and capable of being used on multiple parts of the whole body, thereby being suitable for adult patients, children patients and other patients.
Determine the glutathione-s-transferase theta (GSTT1) or glutathione-s-transferase mu (GSTM1) null genotype is more frequent in individuals with t-MDS/AML. Determine the GSTT1 or GSTM1 null genotype is associated with a reduced incidence of relapse of sarcoma. Determine NAT2 or CYP1A1 genotype influences risk of t-MDS/AML. Determine development of a "mutator phenotype" as demonstrated by developing microsatellite instability is an early marker of individuals likely to progress to t-MDS/AML.
PURPOSE: An extract of rice, rice bran, or rice husks is provided to be used as a natural anti-histamine agent, to prevent or treat allergic rhinitis, inflammatory bowel diseases, asthma, bronchitis, vomiting, gastric and duodenal ulcer, gastroesophageal reflux, sleep disorder, anxiety, and depression without side effects. CONSTITUTION: A pharmaceutical composition for suppressing activity of a histamine receptor contains an extract of rice, rice bran, or rice husks as an active ingredient. The pharmaceutical composition is used for preventing or treating allergic rhinitis, inflammatory bowel disease, asthma, bronchitis, vomiting, gastric and duodenal ulcer, gastroesophageal reflux, sleep disorder, anxiety, and depression. The extract is prepared by using water, an organic solvent, or a mixture thereof. The organic solvent is selected among low carbon number alcohol, hexane, acetone, ethyl acetate, chloroform, and diethyl ether. [Reference numerals] (AA) Hypnagogue time(minutes); (BB) BEE-H sub-fraction(250mg/kg)
When used by direct instillation, 1 to 2 mL of solution may be given as often as every hour.

When used for the routine nursing care of patients with tracheostomy, 1 to 2 mL of solution may be given every 1 to 4 hours by instillation into the tracheostomy.

Acetylcysteine solution may be introduced directly into a particular segment of the bronchopulmonary tree by inserting (under local anesthesia and direct vision) a small plastic catheter into the trachea. Two to 5 mL of the solution may then be instilled by means of a syringe connected to the catheter.

Acetylcysteine solution may also be given through a percutaneous intratracheal catheter. One to 2 mL of the solution every 1 to 4 hours may then be given by a syringe attached to the catheter.
Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. Granulocyte-macrophage colony-stimulating factor (GM-CSF) hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
Systems and methods are disclosed that access over a network a set of codes and respective code descriptions from a first data store. Course data for courses is accessed over a network from a second data store. Code descriptions and course data are compared, and the comparison is used to generate a mapping of courses to codes. The network interface is used to access codes associated with patient records for a plurality of patients from an electronic medical record system associated with a medical service provider. Relevancy values are calculated for codes using the codes associated with patient records. The calculated relevancy values and the accessed mapping of courses to codes are used to generate a first ranked presentation of recommended courses. A course selection is detected. Using the selection, a second ranked presentation of recommended courses is generated by a learning engine with updated learning engine weights.
The invention discloses phytochemical enhanced water. According to the invention, a method and formulation for fluids, such as drinking water, containing plant phytochemicals are disclosed. Some plants can survive in water without a root system, and the formulation includes fluid, such as water, with one or more of the plants maintained in the fluid. Cold storage resulted in enhanced production and excretion of phytochemicals from the plants into the fluid, including bacosides and bacopasides. These phytochemicals have been shown to exhibit antioxidant properties, promote memory and provide additional health benefits, as well as replace bottled water or other fluids as a means to ensure proper hydration. The fluids are useful for enhancing alertness.
BACKGROUND Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia (Ph) chromosome, which results from the fusion of the translocation of the ABL1 gene from chromosome 9 to the BCR gene located in chromosome 22, forming the BCR-ABL gene on chromosome number 22, which accounts for approximately 95% of CML cases. Complex translocation involving other chromosomes can occur. CASE REPORT We present a rare case of CML with a variant Ph chromosome, in which chromosome 16 was involved with the usual translocation. A 34-year-old woman presented with a history of left upper quadrant pain and excessive sweating, with no hepatosplenomegaly on examination. She was found to have leukocytosis, with elevated neutrophils (34 000/mm³), basophils (1460/mm³), and eosinophils (2650/mm³). Karyotyping showed a translocation (16;22) (q24,q11.2), and FISH analysis showed BCR-ABL fusion as a result of (9,22) translocation, with a third chromosome (chromosome 16) involved and fused with chromosome 22, with a different breakpoint, which has never been reported in the literature, affecting the long arm of chromosome 16. The patient was treated with a first-generation tyrosine kinase inhibitor (imatinib) and achieved a deep molecular remission. The repeated FISH analysis confirmed the disappearance of both translocations (9,22) and (16,22). CONCLUSIONS The impact of the additional chromosomal aberration in CML is widely heterogeneous, and the outcome is dependent on multiple factors. Larger studies are needed to clarify the outcome in CML with variant Ph chromosomes, as most of the available data come from reported cases.
PURPOSE:To prepare a latex reagent of high sensitivity having non-specific aggregation, by treating with serum a latex which is obtained by causing styrene containing less than 10wt% of styrene sulfonic acid salt to copolymerize in the water and by heating the copolymerized styrene with an alkaline fluid. CONSTITUTION:Styrene containing 0.001%-5% of styrene sodium sulfonate is caused to copolymerize in the water under the temp. range of 60-85 deg.C without using an emulsifier, but with a ammoinum peroxysulfate used as a starting agent. Latex particles thus obtained are heated under alkaline condition at temp. 60-85 deg.C for 15-100hr. This heating is to be carried out with a reaction system mintained at the range of pH8-11.5, but this condition can be realized by replacing oxygen inside a polymerizing reactor with inert gas such as nitrogen gas, helium, etc. Latex particles obtained by this method are uniform in diameter and very stable even if they contain no emulsifier at all.
The invention relates to applications of a compound in preparation of medicines protecting blood vessel endothelia and anti-oxidative medicines, and belongs to the natural medicine field. The invention provides a compound protecting endothelial cells from oxidative damage caused by ox-LDL. The compound is 15,16-dihydrotanshinone I which is extracted from salvia miltiorrhiza. 15,16-dihydrotanshinone I can improve decrease of the cell survival rate of EA.hy926 and SOD enzyme activity in cells caused by ox-LDL stimulation, and can activate ARE elements in the Nrf2 downstream. The function of protecting endothelial cells may be achieved through inducible expression of a plurality of antioxidant enzymes after activation of Nrf2-ARE passage. A new mean is provided for 15,16-dihydrotanshinone I in treating cardiovascular diseases.
Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearrangement. CCND1 translocations and overexpression have been identified in occasional aggressive B-cell lymphomas with unusual features for MCL. The mechanism generating CCND1 rearrangements in these tumors and their genomic profile are not known. We have reconstructed the IG::CCND1 translocations and the genomic profile of 13 SOX11-negative aggressive B-cell lymphomas using whole genome/exome and target sequencing. The mechanism behind the translocation was an aberrant V(D)J rearrangement in three tumors and by an anomalous IGH class-switch recombination (CSR) or somatic hypermutation (SHM) mechanism in ten. The tumors with a V(D)J-mediated translocation were two blastoid MCL and one high-grade B-cell lymphoma. None of them had a mutational profile suggestive of DLBCL. The ten tumors with CSR/SHM-mediated IGH::CCND1 were mainly large B-cell lymphomas, with mutated genes commonly seen in DLBCL and BCL6 rearrangements in 6. Two cases, which transformed from marginal zone lymphomas, carried mutations in KLF2, TNFAIP3 and KMT2D. These findings expand the spectrum of tumors carrying CCND1 rearrangement that may occur as a secondary event in DLBCL mediated by aberrant CSR/SHM and associated with a mutational profile different from that of MCL.
Parents will be given approximately 5 minutes to review a questionnaire we developed using participant responses in Phase 1. After reviewing the questionnaire, participants will be asked to participate in a semi-structured interview with one of the investigators.
Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
<P>PROBLEM TO BE SOLVED: To prevent an interpretation doctor from failing to see diseases which are not the target of examination without using a communication system such as a network, when the interpretation doctor conducts interpretation for the purpose of a specific examination.  <P>SOLUTION: Without regard to the purpose of the interpretation by the interpretation doctor, a PACS (picture archiving and communication system) 30 determines the kind of automatic measurement processing on the basis of incidental information of medical image data, conducts the determined kind of automatic measurement processing of the image data, and generates numerical report information. Then, the PACS 30 stores the medical image data and the numerical report information in a medium 50. An interpretation terminal 40 reads the content of the medium 50. Then, when the numerical value of the examination in the numerical report information stored in the medium 50 is an abnormal value, the interpretation terminal 40 displays a warning to that effect.  <P>COPYRIGHT: (C)2011,JPO&INPIT